James P. Allison Institute
MD Anderson at AACR
At the core of MD Anderson’s approach to patient care is our pioneering basic science and practice-changing translational research. Our unique environment accelerates novel concepts faster than ever before by offering leading scientific minds close proximity to the clinics to ease collaboration with our renowned clinicians. At the 2022 American Association of Cancer Research Annual Meeting, our experts will showcase their pacesetting research and join colleagues from across the globe for discussion on the latest advances in cancer science.
Below are highlights from our presentations, details about onsite networking opportunities with our experts and information on open research positions at MD Anderson.
Featured Articles
New
platform optimizes selection of combination cancer therapies
Bioinformatics approach predicts combinations with
improved outcomes in pre-clinical and clinical studies
AACR:
Combination immunotherapy treatment effective before lung cancer
surgery
Translational findings support
combinations over single-agent therapy
Therapies targeting DNA damage response show promising antitumor activity
New data from MD Anderson-led studies on ATR inhibitor and next-generation PARP1 inhibitor presented at AACR Annual Meeting
Meet the Experts
Visit booth 1901 to ask a question, learn about training and career opportunities and continue the conversation on key presentations with our experts.
Sunday, April 10
Peter
WT Pisters, M.D.
MD Anderson
President
1-2 p.m.
Philip
Jones, Ph.D.
1-2 p.m.
Boyi Gan, Ph.D.
2-3 p.m.
Yago Nieto, M.D., Ph.D.
3:30-4:30 pm.
Monday, April 11
Funda Meric-Bernstam, M.D.
10-11 a.m.
Cassian Yee,
M.D.
11 a.m.-12 p.m.
Raghu Kalluri, Ph.D.
12-1 p.m.
Jennifer McQuade, M.D.
2-3 p.m.
Moran Amit, M.D., Ph.D.
3-4 p.m.
Nicholas Navin, Ph.D.
4-5 p.m.
Tuesday, April 12
Timothy Yap, M.B.B.S., Ph.D.
9-9:30 a.m.
Koichi Takahashi, M.D., Ph.D.
11:30 a.m.-12 p.m.
Tina Cascone, M.D., Ph.D.
1-2 p.m.
Jim Allison, Ph.D.
2-3 p.m.
Padmanee Sharma, M.D., Ph.D.
2-3 p.m.
James P. Allison Institute
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
Meet Dr. James Allison, Dr. Padmanee Sharma and Dr. Raghu Kalluri at the AACR annual meeting on Tuesday, April 12 from 2-3 p.m. at booth 1901.
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities from undergraduate degrees to postdoctoral training.
Cancer immunologist: Research at MD Anderson is my calling
From his first encounter as a student in a summer research program to establishing his own lab here, our Dr. Alexandre Reuben shares what sets MD Anderson apart.
Therapeutics Discovery
Our Therapeutics Discovery team consists of dedicated cancer researchers, doctors, drug developers and scientific experts. We develop small molecule drugs, biologics and cellular therapies without the bottlenecks that hamper traditional drug development.
We're inspired by the needs of our patients and guided by the expertise of MD Anderson clinicians. We don't bring the “bench to bedside” – we start with the bench at the bedside – with each patient and their cancer.
Why Houston?
As America's fourth largest city, Houston has a lot to offer. Find out why Houston is a hub for scientific and medical excellence.
Moon Shots Program
MD Anderson’s Moon Shots Program® aims to rapidly and dramatically improve the disease's survival rates and reduce suffering through early detection, research and new treatments.
Learn more about the Moon Shots Program
